Last reviewed · How we verify
MUC1 peptide-poly-ICLC adjuvant vaccine
MUC1 peptide-poly-ICLC adjuvant vaccine is a Biologic drug developed by Joseph Baar, MD, PhD. It is currently in Phase 1 development.
At a glance
| Generic name | MUC1 peptide-poly-ICLC adjuvant vaccine |
|---|---|
| Sponsor | Joseph Baar, MD, PhD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (PHASE1)
- Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (PHASE1, PHASE2)
- Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (PHASE2)
- MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (PHASE1)
- Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma (PHASE2)
- MUC1 Vaccine for Triple-negative Breast Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MUC1 peptide-poly-ICLC adjuvant vaccine CI brief — competitive landscape report
- MUC1 peptide-poly-ICLC adjuvant vaccine updates RSS · CI watch RSS
- Joseph Baar, MD, PhD portfolio CI
Frequently asked questions about MUC1 peptide-poly-ICLC adjuvant vaccine
What is MUC1 peptide-poly-ICLC adjuvant vaccine?
MUC1 peptide-poly-ICLC adjuvant vaccine is a Biologic drug developed by Joseph Baar, MD, PhD.
Who makes MUC1 peptide-poly-ICLC adjuvant vaccine?
MUC1 peptide-poly-ICLC adjuvant vaccine is developed by Joseph Baar, MD, PhD (see full Joseph Baar, MD, PhD pipeline at /company/joseph-baar-md-phd).
What development phase is MUC1 peptide-poly-ICLC adjuvant vaccine in?
MUC1 peptide-poly-ICLC adjuvant vaccine is in Phase 1.